Prezcobix

(cobicistat / darunavir)
Prezcobix 800 MG / 150 MG Oral Tablet
NO BLACK BOX WARNING

Dosage & administration

Recommended dosage: One tablet taken once daily with food in adults and pediatric patients weighing at least 40 kg. ( 2.1)

Testing Prior to Initiation: HIV genotypic testing is recommended for antiretroviral treatment experienced patients. Assess estimated creatinine clearance in all patients prior to starting PREZCOBIX. When used with tenofovir DF: Assess urine glucose and urine protein at baseline and monitor creatinine clearance, urine glucose, and urine protein. Monitor serum phosphorus in patients with or at risk for renal impairment. ( 2.2)

drug label

Prezcobix prescribing information

prior authorization

Prezcobix prior authorization resources

OTHER
Complete Letter of Medical Necessity

PDF
Formulary Exception Checklist

PDF
Formulary Exception Checklist - Spanish
Learn More

Benefits investigation

PDF
Benefits Investigation Form

PDF
Janssen Patient Support Program Patient Authorization Form
Learn More

financial assistance

Prezcobix financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
J & J Patient Assistance Foundation Eligibility Check
Learn More

patient education

Prezcobix patient education

Getting started on Prezcobix

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Learn More

Other resources

Learn More

people also ask

Prezcobix FAQs

How is the dosage of Prezcobix?Prezcobix is available in 1 dosages, including 150-800 mg Tab
What does Prezcobix treat?Prezcobix treats Acquired Immunodeficiency Syndrome and HIV Infections
What is Prezcobix made of?Prezcobix contains cobicistat / darunavir which is a Cytochrome P450 3A Inhibitor
How Is Prezcobix Administered?Prezcobix is administered as a Oral Pill
What Are The Prezcobix Mechanism Of Action?Prezcobix mechanism of action is Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2D6 Inhibitors, Cytochrome P450 3A Inhibitors, HIV Protease Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors, Organic Anion Transporting Polypeptide 1B3 Inhibitors or P-Glycoprotein Inhibitors
FAQ Data Source